𝔖 Bobbio Scriptorium
✦   LIBER   ✦

1164 susceptibility of wild-type and lamivudine-resistant hepatitis B virus to tenofovir and adefovir

✍ Scribed by LADA, O; BENHAMOU, Y; VALANTIN, M; KATLAMA, C; POYNARD, T; CAHOUR, A; THIBAULT, V

Book ID
123167156
Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
144 KB
Volume
38
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Susceptibility of hepatitis B virus to l
Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir
✍ H.L. Zaaijer; R.B. Takkenberg; C.J. Weegink; S.P.H. Rebers; S. Menting; H.W. Ree 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

## Abstract Serial monotherapy and add‐on regimes for treatment of chronic hepatitis B virus (HBV) infection may induce the accumulation of viral resistance mutations in patients, reducing the options for ongoing viral suppression. The induction of antiviral resistance by serial application of poly

Comparison of adefovir and tenofovir in
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection
✍ Florian van Bömmel; Thomas Wünsche; Stefan Mauss; Petra Reinke; Alexandra Bergk; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 1 views

Adefovir dipivoxil was recently approved for the treatment of wild-type and lamivudineresistant hepatitis B virus (HBV) infection. Tenofovir disoproxil fumarate, a congender of adefovir that is used in the treatment of HIV infected patients, has recently been shown to also be effective in patients w

Dynamics of lamivudine-resistant hepatit
Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy
✍ Samreen Ijaz; Catherine Arnold; Samir Dervisevic; Jana Mechurova; Nick Tatman; R 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB

## Abstract Adefovir dipivoxil has been used alone or together with lamivudine to suppress lamivudine‐resistant hepatitis B virus (HBV). However, the dynamics of HBV populations under different selection pressures and their impact on treatment outcome are poorly understood. Pyrosequencing® was appl